[1]
“Comprehensive Analysis Of Biomarkers Predicting Response To Nivolumab + Ipilimumab Combination Therapy In Cancer Treatment”, AJBR, vol. 27, no. 3S, pp. 5596–5606, Oct. 2024, doi: 10.53555/AJBR.v27i3S.3376.